Deferiprone (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Deferiprone" in English language version.

Last modified: 02:28:47, 29 July 2026 (UTC)

Ref.Un. Ref.Website

Global rank English rank

113fda.gov

470^th place

329^th place

103web.archive.org

1^st place

86nih.gov

5^th place

54doi.org

2^nd place

51europa.eu

62^nd place

100^th place

11drugs.com

529^th place

550^th place

11canada.ca

1,114^th place

605^th place

11medicines.org.uk

4,892^nd place

3,451^st place

11cipla.com

low place

11plos.org

2,101^st place

6,885^th place

11thestar.com

395^th place

213^th place

canada.ca (Global: 1,114^th place; English: 605^th place)

"Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.

cipla.com (Global: low place; English: low place)

Staff. "Cipla's History". Cipla. Archived from the original on 27 October 2015.

doi.org (Global: 2^nd place; English: 2^nd place)

Savulescu J (February 2004). "Thalassaemia major: the murky story of deferiprone". BMJ. 328 (7436): 358–9. doi:10.1136/bmj.328.7436.358. PMC 341373. PMID 14962851.
Viens AM, Savulescu J (February 2004). "Introduction to The Olivieri symposium". Journal of Medical Ethics. 30 (1): 1–7. doi:10.1136/jme.2003.006577. PMC 1757126. PMID 14872065.
Brittenham GM, Nathan DG, Olivieri NF, Porter JB, Pippard M, Vichinsky EP, Weatherall DJ (June 2003). "Deferiprone and hepatic fibrosis". Blood. 101 (12): 5089–90, author reply 5090–1. doi:10.1182/blood-2002-10-3173. PMID 12788794.
Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, et al. (September 2002). "Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia". Blood. 100 (5): 1566–9. doi:10.1182/blood-2002-01-0306. PMID 12176871.

drugs.com (Global: 529^th place; English: 550^th place)

"Deferiprone (Ferriprox) Use During Pregnancy". Drugs.com. 30 March 2020. Retrieved 20 May 2020.

europa.eu (Global: 62^nd place; English: 100^th place)

ema.europa.eu

"Ferriprox EPAR". European Medicines Agency (EMA). 28 October 2009. Retrieved 20 May 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

fda.gov (Global: 470^th place; English: 329^th place)

accessdata.fda.gov

"Drug Approval Package: Ferriprox (deferiprone) Tablet NDA #021825". U.S. Food and Drug Administration (FDA). 30 November 2011. Retrieved 20 May 2020.
"Deferiprone: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 19 October 2020. Retrieved 20 May 2020.

fda.gov

"FDA Approves Ferripox (deferiprone) to Treat Patients with Excess Iron in the Body". U.S. Food and Drug Administration (FDA) (Press release). 14 October 2011. Archived from the original on 10 October 2016. This article incorporates text from this source, which is in the public domain.

medicines.org.uk (Global: 4,892^nd place; English: 3,451^st place)

"Ferriprox 100 mg/ml oral solution - Summary of Product Characteristics (SmPC)". (emc). 26 November 2019. Retrieved 20 May 2020.

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Savulescu J (February 2004). "Thalassaemia major: the murky story of deferiprone". BMJ. 328 (7436): 358–9. doi:10.1136/bmj.328.7436.358. PMC 341373. PMID 14962851.
Viens AM, Savulescu J (February 2004). "Introduction to The Olivieri symposium". Journal of Medical Ethics. 30 (1): 1–7. doi:10.1136/jme.2003.006577. PMC 1757126. PMID 14872065.
Brittenham GM, Nathan DG, Olivieri NF, Porter JB, Pippard M, Vichinsky EP, Weatherall DJ (June 2003). "Deferiprone and hepatic fibrosis". Blood. 101 (12): 5089–90, author reply 5090–1. doi:10.1182/blood-2002-10-3173. PMID 12788794.
Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, et al. (September 2002). "Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia". Blood. 100 (5): 1566–9. doi:10.1182/blood-2002-01-0306. PMID 12176871.

ncbi.nlm.nih.gov

Savulescu J (February 2004). "Thalassaemia major: the murky story of deferiprone". BMJ. 328 (7436): 358–9. doi:10.1136/bmj.328.7436.358. PMC 341373. PMID 14962851.
Viens AM, Savulescu J (February 2004). "Introduction to The Olivieri symposium". Journal of Medical Ethics. 30 (1): 1–7. doi:10.1136/jme.2003.006577. PMC 1757126. PMID 14872065.

plos.org (Global: 2,101^st place; English: 6,885^th place)

journals.plos.org

Deepti Saxena, Michael Spino, Fernando Tricta, John Connelly, Bernadette M. Cracchiolo, Axel-Rainer Hanauske, Darlene D’Alliessi Gandolfi, Michael B. Mathews, Jonathan Karn, Bart Holland, Myung Hee Park, Tsafi Pe’ery, Paul E. Palumbo, Hartmut M. Hanauske-Abel (18 May 2016). Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial.

thestar.com (Global: 395^th place; English: 213^th place)

Cribb R (27 February 2019). "UHN patients given unlicensed drug that led to diabetes, liver dysfunction and one death, study finds". The Star. Toronto. Retrieved 27 February 2019.

web.archive.org (Global: 1^st place; English: 1^st place)

Staff. "Cipla's History". Cipla. Archived from the original on 27 October 2015.
"FDA Approves Ferripox (deferiprone) to Treat Patients with Excess Iron in the Body". U.S. Food and Drug Administration (FDA) (Press release). 14 October 2011. Archived from the original on 10 October 2016. This article incorporates text from this source, which is in the public domain.
"Deferiprone: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 19 October 2020. Retrieved 20 May 2020.

Deferiprone (English Wikipedia)

canada.ca (Global: 1,114th place; English: 605th place)

cipla.com (Global: low place; English: low place)

doi.org (Global: 2nd place; English: 2nd place)

drugs.com (Global: 529th place; English: 550th place)

europa.eu (Global: 62nd place; English: 100th place)